COVID-19

FDA voted in favor of approving the Abrysvo vaccine | Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years |
Statement on the antigen composition of COVID-19 vaccines |
Canine Olfactory Detection of SARS-CoV-2-Infected Humans | CDC HIV surveillance report

Risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses: an electronic health record-based analysis from the RECOVER initiative | Trajectories of the evolution of post COVID-19 condition, up to two years after symptoms onset | Virus variant specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on omicron VOC. | COVID-19 mortality among selective serotonin reuptake inhibitor users – Results from a nationwide cohort | Efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19: results of a randomized controlled trial

Impact of SARS-CoV-2 Variants on Inpatient Clinical Outcome |
Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial |
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults | Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth |
Vaccines and Related Biological Products Advisory Committee Meeting June 15, 2023 Announcement | Gut microbiota‐derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19: An open‐label pilot study |
COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration |
Provisional Mortality Data |
Prevalence of Post-Coronavirus Disease Condition 12 Weeks After Omicron Infection Compared With Negative Controls and Association With Vaccination Status

Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA | U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States | Vaccination with BCG-Denmark did not result in a lower risk of Covid-19 among health care workers than placebo |NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial | Comparative effectiveness of the sars-CoV-2 vaccines during Delta dominance | Clinical Outcomes Following Treatment for COVID-19 | Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study | Association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market | Researchers disagree over how bad it is to be reinfected, and whether COVID-19 can cause lasting changes to the immune system | Virtual Care and Emergency Department Use During the COVID-19 Pandemic Among Patients of Family Physicians in Ontario, Canada | Assessment of Gender-Specific COVID-19 Case Fatality Risk per Malignant Neoplasm Type | Timing of intubation and ICU mortality in COVID-19 patients

SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis | Completeness and Spin of medRxiv Preprint and Associated Published Abstracts of COVID-19 Randomized Clinical Trials | Risk of new-onset Long Covid following reinfection with SARS-CoV-2: community-based cohort study |
Low vitamin D levels are associated with Long COVID syndrome in COVID-19 survivors | Effectiveness of Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine | Molnupiravir and risk of post-acute sequelae of COVID-19 | Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19” | Lessons Learned From a COVID-19 Dog Screening Pilot in California K-12 Schools

Update on Vaccine-Derived Poliovirus Outbreaks | Sleep Disturbance Severity and Correlates |
Two individuals with potential monkeypox virus reinfection | Risk of autoimmune diseases in patients |
FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines | SARS-CoV-2 neutralizing antibodies | Durability of Bivalent Boosters against Omicron Subvariants | Nirmatrelvir and risk of hospital admission or death in adults | Evolving Real-World Effectiveness of Monoclonal Antibodies | Effect of Angiotensin-Converting Enzyme Inhibitor | Efficacy and Safety of Anakinra Plus Standard | Higher dose corticosteroids in patients admitted to hospital | Risk of Death in Patients Hospitalized for COVID-19 | Recent French mpox cluster includes fully vaccinated patients | Epidemiologic and Clinical Features of Mpox-Associated Deaths | SARS-CoV-2 During Omicron Variant Predominance | Severe Maternal Morbidity and Mortality of Pregnant Patients | Sickness presenteeism in healthcare workers | Ventilation Improvements Among K–12 Public School Districts | Risk factors and vectors for SARS-CoV-2 household transmission | Definition of Post–COVID-19 Condition

Prevalence and Characteristics Associated With Post–COVID-19 Condition | The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection |
Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome | Vaccine effectiveness against hospitalization among adolescent cases |
Effectiveness of BNT162b2 after extending the primary series dosing interval in children | Within-host genetic diversity of SARS-CoV-2 |
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants | Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection |
COVID-19 convalescent plasma utilization in the United States |
FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19 | Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients |
Anti-C5a antibody (vilobelimab) therapy for critically ill patients |
Triple combination therapy with two antivirals | Adeno-associated virus type 2 in US children | Genomic investigations of unexplained acute hepatitis in children | Surveillance of SARS-CoV-2 at the Huanan Seafood Market

Severe Infection and Risk of Cardiovascular Disease | Risk Factors Associated With Post−COVID-19 Condition | Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization | Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition |
Antibiotics don’t reduce risk of death from viral respiratory infections |
ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study |
Mechanically Ventilated Patients With Coronavirus Disease 2019 Had a Higher Chance of In-Hospital Death If Treated With High-Flow Nasal Cannula Oxygen Before Intubation

Prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction | A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story | Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households | Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system |
Projected COVID-19 Mortality Reduction From Paxlovid Rollout |
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity | Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis | Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers

Clinical Characteristics and Outcomes of Children With SARS-CoV-2 Infection During the Delta and Omicron Variant-Dominant Periods in Korea | Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19 | Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection | Outpatient Treatment of COVID-19 and the Development of Long COVID Over 10 Months |
Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19 |
Optimal Duration of Systemic Corticosteroids in COVID-19 Treatment | SARS-CoV-2 Exposure in Norway Rats (Rattus norvegicus) from New York City | Exhaled Breath Aerosol Shedding of Highly Transmissible Versus Prior Severe Acute Respiratory Syndrome Coronavirus 2 Variants